Ligand Historical Cash Flow
| LGND Stock | USD 121.47 1.08 0.88% |
Analysis of Ligand Pharmaceuticals cash flow over time is an excellent tool to project Ligand Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Capital Expenditures of 6.6 M or Total Cash From Operating Activities of 52.1 M as it is a great indicator of Ligand Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Ligand Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Ligand Pharmaceuticals is a good buy for the upcoming year.
Ligand |
About Ligand Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Ligand balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Ligand's non-liquid assets can be easily converted into cash.
Ligand Pharmaceuticals Cash Flow Chart
Add Fundamental
Capital Expenditures
Capital Expenditures are funds used by Ligand Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Ligand Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Ligand Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Ligand Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Ligand Pharmaceuticals Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At present, Ligand Pharmaceuticals' Depreciation is projected to increase significantly based on the last few years of reporting. The current year's Capital Expenditures is expected to grow to about 6.6 M, whereas Free Cash Flow is forecasted to decline to (4.5 M).
Ligand Pharmaceuticals cash flow statement Correlations
Click cells to compare fundamentals
Ligand Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ligand Pharmaceuticals cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (47.5M) | (24.3M) | (28.4M) | 25.5M | (22.1M) | (20.9M) | |
| Free Cash Flow | (31.9M) | 50.1M | 70.0M | 119.9M | (4.3M) | (4.5M) | |
| Change In Working Capital | (4.2M) | (10.1M) | (52.2M) | 65.7M | (34.4M) | (32.7M) | |
| Begin Period Cash Flow | 119.8M | 72.3M | 48.0M | 19.5M | 45.0M | 49.8M | |
| Other Cashflows From Financing Activities | (4.8M) | (789K) | 8.2M | (6.8M) | 17.0M | 16.1M | |
| Depreciation | 43.7M | 28.0M | 50.9M | 51.4M | 35.6M | 37.4M | |
| Other Non Cash Items | (797.5M) | 28.0M | (7.3M) | (26.8M) | (41.3M) | (43.3M) | |
| Capital Expenditures | 2.6M | 4.5M | 8.8M | 17.9M | 3.5M | 6.6M | |
| Total Cash From Operating Activities | (29.3M) | 54.6M | 78.8M | 137.9M | 49.6M | 52.1M | |
| Net Income | 629.3M | (3.0M) | 57.1M | (33.4M) | 52.2M | 54.8M | |
| Total Cash From Financing Activities | (485.2M) | (310.5M) | (137.8M) | (276.0M) | (59.9M) | (56.9M) | |
| End Period Cash Flow | 72.3M | 48.0M | 19.5M | 45.0M | 23.0M | 21.8M | |
| Change To Inventory | (2.1M) | (17.8M) | (427K) | 12.1M | (10.9M) | (10.3M) | |
| Total Cashflows From Investing Activities | 466.9M | 231.6M | 30.5M | 163.6M | 147.3M | 154.6M | |
| Other Cashflows From Investing Activities | 796.3M | (379.6M) | (1.2M) | (960K) | (864K) | (820.8K) | |
| Change To Liabilities | (4.4M) | (4.6M) | (15.1M) | (9.6M) | (8.7M) | (8.2M) | |
| Change To Account Receivables | 25.5M | (26.1M) | (28.6M) | 55.3M | (2.6M) | (2.5M) | |
| Sale Purchase Of Stock | (453.0M) | (78.0M) | (18.4M) | (8.2M) | (4.5M) | (4.8M) | |
| Stock Based Compensation | 24.5M | 30.7M | 38.8M | 60.3M | 25.7M | 17.4M | |
| Investments | (326.8M) | 615.7M | 40.0M | 163.6M | (8.7M) | (9.1M) | |
| Change Receivables | (29.5M) | 25.5M | (26.1M) | (28.6M) | (25.8M) | (24.5M) | |
| Net Borrowings | (27.3M) | (222.2M) | (164.9M) | (261.0M) | (234.9M) | (223.2M) | |
| Cash And Cash Equivalents Changes | 99.4M | (47.6M) | (24.3M) | (28.4M) | (25.6M) | (24.3M) | |
| Cash Flows Other Operating | 25.1M | 2.2M | 57.6M | (18.0M) | (16.2M) | (15.4M) | |
| Change To Netincome | (717.9M) | (1.8M) | 6.2M | 47.9M | 43.1M | 45.3M | |
| Change To Operating Activities | (9.6M) | (3.3M) | (4.1M) | 6.3M | 7.3M | 7.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ligand Pharmaceuticals is a strong investment it is important to analyze Ligand Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ligand Pharmaceuticals' future performance. For an informed investment choice regarding Ligand Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Ligand Pharmaceuticals Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ligand Pharmaceuticals. If investors know Ligand will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ligand Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.032 | Earnings Share 2.49 | Revenue Per Share 8.509 | Quarterly Revenue Growth 0.576 | Return On Assets 0.013 |
The market value of Ligand Pharmaceuticals is measured differently than its book value, which is the value of Ligand that is recorded on the company's balance sheet. Investors also form their own opinion of Ligand Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ligand Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ligand Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ligand Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ligand Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ligand Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ligand Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.